Clinicopathological and prognostic significance of CDK16 in patients with intrauterine membrane carcinoma
-
摘要:
目的 探讨CDK16在子宫内膜癌(EC)中表达的临床病理和预后意义，为评估EC预后提供评估指标。 方法 回顾性分析2019年2月—2022年12月在蚌埠医科大学第一附属医院诊断为子宫内膜癌并接受治愈性手术的96例子宫内膜癌患者及同时期15例正常子宫内膜组织蜡块的资料。收集患者的临床病理信息，采用免疫组织化学方法检测CDK16蛋白的表达，并探讨CDK16的不同表达水平与子宫内膜癌患者的临床病理参数以及预后的相关性。 结果 CDK16在正常的内膜组织细胞和子宫内膜癌组织中高表达率为20.0%(3/15)、67.7%(65/96)，子宫内膜癌组织中CDK16高表达率明显高于正常的内膜组织(P＜0.05)。CDK16在FIGOⅠ期和FIGOⅡ期、FIGOⅢ期患者中的高表达率分别为61.0%(47/77)和94.8%(18/19)，CDK16在无淋巴结转移患者和有淋巴结转移患者中的高表达率分别为65.9%(58/88)和87.5%(7/8)，无脉管浸润患者的CDK16高表达率低于有脉管浸润患者(P＜0.05)。多因素Cox比例风险模型结果显示，FIGO分期、淋巴结转移、CDK16表达强度均为无进展生存期(PFS)和总生存期(OS)的影响因素(P＜0.05)。 结论 CDK16在子宫内膜癌组织中表达增强，是子宫内膜癌潜在的预后标志物。 Abstract:Objective To investigate the clinicopathological and prognostic significance of CDK16 expression in intrauterine carcinoma (EC), and to provide an evaluation index for the prognosis of EC. Methods A retrospective study was conducted on 96 patients with endometrial cancer who were diagnosed and underwent curative surgery at the First Affiliated Hospital of Bengbu Medical University between February 2019 and December 2022, along with 15 normal endometrial tissue block specimens from the same period. Clinicopathological information was collected and the expression of CDK16 protein was detected by immunohistochemistry. The relationship between the different expression levels of CDK16 and the clinicopathological parameters and prognosis of patients with intrauterine membrane carcinoma were explored. Results The high expression rates of CDK16 in normal endometrial tissues and endometrial cancer tissues were 20.0% (3/15) and 67.7% (65/96), respectively. The high expression rate of CDK16 in endometrial cancer tissues was significantly higher than that in normal endometrial tissues (P < 0.05). The high expression rates of CDK16 in FIGO stage Ⅰ/Ⅱ and FIGO stage Ⅲ patients were 61.0% (47/77) and 94.8% (18/19), respectively. The high expression rates of CDK16 in patients without lymph node metastasis and those with lymph node metastasis were 65.9% (58/88) and 87.5% (7/8), respectively. The high expression rate of CDK16 in patients without vascular invasion was lower than that in patients with vascular invasion (P < 0.05). Multivariate Cox proportional hazards model results showed that FIGO stage, lymph node metastasis, CDK16 expression intensity were influencing factors of pro-gression-free survival (PFS) and overall survival (OS), P < 0.05. Conclusion The expression of CDK16 is enhanced in intrauterine carcinoma. CDK16 is a potential prognostic marker for intrauterine carcinoma. -
Key words:
- Endometrial carcinoma /
- CDK16 /
- Prognosis
-
图 1 子宫内膜癌组织与正常内膜组织CDK16的表达情况(MaxVisionTM免疫组化法)
Figure 1. Expression of CDK16 in endometrial cancer patient tissues and normal endometrial tissues (MaxVision? immunohistochemical method)
表 1 子宫内膜癌组织与正常内膜组织CDK16表达情况比较(例)
Table 1. Comparison of the positive rate of CDK16 expression in endometrial cancer tissue and normal endometrial tissue (cases)
组别 例数 低表达 高表达 χ2值 P值 内膜癌组织 96 31 65 12.442 0.001 正常内膜组织 15 12 3 
下载: 导出CSV
表 2 不同临床及病理特征子宫内膜癌患者CDK16表达强度比较(例)
Table 2. Comparison of CDK16 expression intensity in patients with different clinical and pathological characteristics (cases)
项目 例数 低表达 高表达 χ2值 P值 FIGO分期 ⅠA+ⅡB 77 30 47 7.915 0.005 Ⅱ+Ⅲ 19 1 18 组织学分级 G1/G2 77 27 50 1.369 0.242 G3 19 4 15 淋巴结转移 无 88 30 58 13.883 ＜0.001 有 8 1 7 脉管转移 无 91 31 60 2.516 0.003 有 5 0 5 浸润深度 ＜1/2肌层 67 29 38 23.734 ＜0.001 ≥1/2肌层 29 2 27
下载: 导出CSV
表 3 不同CDK16表达强度及病理特征子宫内膜癌患者PFS、OS比较(月)
Table 3. Comparison of PFS and OS in patients with endometrial cancer based on different expression intensities of CDK16 and their pathological characteristics (month)
项目 例数 PFS log-rank
χ2值P值 OS log-rank
χ2值P值 FIGO分期 9.224 0.002 10.465 0.001 ⅠA+ⅠB 77 32.0 39.0 Ⅱ+Ⅲ 19 25.0 31.0 组织学分级 3.067 0.080 2.484 0.115 G1+G2 77 31.0 39.0 G3 19 27.0 33.0 淋巴结转移 14.618 ＜0.001 18.365 ＜0.001 否 88 32.0 39.0 是 8 20.0 24.0 脉管转移 0.297 0.586 0.418 0.518 否 91 31.0 38.0 是 5 32.0 33.0 浸润深度 0.068 0.794 0.172 0.679 ＜1/2肌层 67 32.0 39.0 ≥1/2肌层 29 28.0 34.0 年龄 8.083 0.004 7.182 0.007 ＜60岁 66 32.0 38.0 ≥60岁 30 29.0 37.0 CDK16表达强度 129.659 ＜0.001 102.626 ＜0.001 1 13 47.0 47.0 2 9 39.0 39.0 4 9 32.0 42.0 6 28 34.0 41.0 8 21 30.0 35.0 9 11 12.0 27.0 12 5 8.0 17.0
下载: 导出CSV
表 4 子宫内膜癌患者PFS、OS影响因素的Cox回归分析
Table 4. Cox regression analysis of the relationship between PFS and OS in endometrial carcinoma
变量 PFS OS HR(95% CI) P值 HR(95% CI) P值 FIGO分期 4.502(1.200~16.890) 0.026 4.885(1.270~18.780) 0.021 组织学分级 0.035(0.001~1.500) 0.277 0.037(0.001~1.600) 0.324 淋巴结转移 6.223(1.400~27.650) 0.017 7.630(1.700~34.200) 0.007 脉管转移 0.248(0.020~2.500) 0.267 0.255(0.020~2.600) 0.251 浸润深度 0.833(0.200~3.500) 0.787 0.898(0.200~3.800) 0.875 年龄 1.174(1.100~1.250) ＜0.001 1.156(1.080~1.230) 0.001 CDK16表达强度 129.659(50.000~336.000) ＜0.001 102.626(40.000~263.000) ＜0.001
下载: 导出CSV
-
[1] 陈晓军, 张剑峰, 陆雯, 等. 子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637.CHEN X J, ZHANG J F, LU W, et al. Chinese expert consensus on quality control and evaluation standards for surgical treatment of endometrial cancer (2024 edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2024, 40(6): 626-637. [2] 颜舜轩, 黄涛, 黄佳佳, 等. 子宫内膜癌MKI67表达与预后的相关性[J]. 医药论坛杂志, 2024, 45(15): 1578-1585.YAN S X, HUANG T, HUANG J J, et al. The correlation between MKI67 expression in endometrial cancer and prognosis[J]. Journal of Medical Forum, 2024, 45(15): 1578-1585. [3] 张岩, 江路, 燕鑫. 子宫内膜癌免疫检查点阻断治疗的进展[J]. 中国医刊, 2021, 56(8): 833-836.ZHANG Y, JIANG L, YAN X. Progress in immune checkpoint blockade therapy for endometrial cancer[J]. Chinese Journal of Medicine, 2021, 56(8): 833-836. [4] 洪小惠. 子宫内膜癌中ER、PR、P53、Ki-67及Vimentin的表达及临床意义[D]. 福州: 福建医科大学, 2021.HONG X H. The expression of ER, PR, P53, Ki-67 and Vimentin in endometrial carcinoma and its clinical significance[D]. Fuzhou: Fujian Medical University, 2021. [5] GU X H, SHEN H H, BAI W Q, et al. Endometrial cancer prognosis prediction using correlation models based on CDK family genes[J]. Front Genet, 2022, 13: 1021600. DOI: 10.3389/fgene.2022.1021600. [6] 邵卓伟, 吴仕波. CDK16在人类癌症中的作用与机制[J]. 生命的化学, 2024, 44(2): 233-242.SHAO Z W, WU S B. The role and mechanism of CDK16 in human cancer[J]. Chemical Life, 2024, 44(2): 233-242. [7] WANG X, LIU R Q, LI S, et al. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers[J]. Biomed Pharmacother, 2023, 164: 114929. DOI: 10.1016/j.biopha.2023.114929. [8] 杨垲威, 唐开, 廖霞, 等. 基于生物信息学研究CDK1在ACC中的表达及临床意义[J]. 医学理论与实践, 2024, 37(16): 2701-2705, 2727.YANG K W, TANG K, LIAO X, et al. Expression of CDK1 in ACC and its clinical significance based on bioinformatics research[J]. Medical Theory and Practice, 2024, 37(16): 2701-2705, 2727. [9] 郭勤浩, 余敏, 吴小华. 2022年度妇科肿瘤诊治进展[J]. 中国癌症杂志, 2023, 33(1): 14-24.GUO Q H, YU M, WU X H. Progress in diagnosis and treatment of gynecological tumors in 2022[J]. Chinese Journal of Cancer, 2023, 33(1): 14-24. [10] 沈晓瑜, 贾岳, 杨志芹, 等. 子宫内膜癌流行病学趋势及危险因素的研究进展[J]. 华南预防医学, 2022, 48(9): 1079-1081, 1086.SHEN X Y, JIA Y, YANG Z Q, et al. Epidemic disease and risk factors of endometrial cancer[J]. Huanan Preventive Medicine, 2022, 48(9): 1079-1081, 1086. [11] 张心, 王建东. 子宫内膜癌相关流行病学高危因素的研究进展[J]. 医学综述, 2021, 27(15): 2995-2999.ZHANG X, WANG J D. Research progress on epidemiological risk factors related to endometrial cancer[J]. Medical Recapitulate, 2021, 27(15): 2995-2999. [12] 邢莹, 余姝婷, 朱小利. LncRNA XIST在子宫内膜癌组织中的表达及其靶向microRNA-101-3p对癌细胞生物行为学的影响[J]. 中国现代医学杂志, 2022, 32(21): 24-30.XING Y, YU S T, ZHU X L. Expression of LncRNA XIST in endometrial cancer tissues and its targeting of microRNA-101-3p on the biological behavior of cancer cells[J]. Chinese Journal of Modern Medicine, 2022, 32(21): 24-30. [13] 王莹, 夏潇, 韩恩善. 子宫内膜癌中Ki-67及COL17A1表达水平与临床病理及预后关系[J]. 宁夏医学杂志, 2024, 46(8): 705-708.WANG Y, XIA X, HAN E S. Expression levels of Ki-67 and COL17A1 in endometrial cancer and their relationship with clinicopathology and prognosis[J]. Ningxia Medical Journal, 2024, 46(8): 705-708. [14] 谷保双, 赵彩琴, 徐方方. 肥胖、高血糖和高脂血症与子宫内膜癌患者临床特征的关系[J]. 新乡医学院学报, 2025, 42(2): 133-137, 142.GU B S, ZHAO C Q, XU F F. The relationship of obesity, hyperglycemia, and hyperlipidemia with clinical characteristics in patients with endometrial cancer[J]. Journal of Xinxiang Medical University, 2025, 42(2): 133-137, 142. [15] 沈晓瑜, 贾岳, 杨志芹, 等. 子宫内膜癌流行病学趋势及危险因素的研究进展[J]. 华南预防医学, 2022, 48(9): 1079-1081, 1086.SHEN X Y, JIA Y, YANG Z Q, et al. Research progress on epidemiological trends and risk factors of endometrial cancer[J]. South China Journal of Preventive Medicine, 2022, 48(9): 1079-1081, 1086. [16] 吴倩华, 李碧岚. 子宫内膜癌免疫治疗的进展及现状[J]. 现代妇产科进展, 2022, 31(5): 389-393.WU Q H, LI B L. Progress and current status of immunotherapy for endometrial cancer[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 389-393. [17] 刘逸贤, 陈嵘, 程忠平. 免疫治疗在晚期或复发性子宫内膜癌中的应用进展[J]. 中华全科医学, 2023, 21(10): 1753-1756, 1797. doi: 10.16766/j.cnki.issn.1674-4152.003217LIU Y X, CHEN R, CHENG Z P. Advances in the application of immunotherapy for advanced or recurrent endometrial cancer[J]. Chinese Journal of General Practice, 2023, 21(10): 1753-1756, 1797. doi: 10.16766/j.cnki.issn.1674-4152.003217 [18] 顾园, 李平, 李晶. CDK14和FOLR1在结肠癌组织中的表达及与患者临床病理特征和预后的关系[J]. 国际消化病杂志, 2024, 44(2): 88-93.GU Y, LI P, LI J. Expression of CDK14 and FOLR1 in colon cancer tissues and their relationship with clinicopathological features and prognosis[J]. International Journal of Digestive Diseases, 2024, 44(2): 88-93. [19] YANG Q, YU H, LI Q. Genome-Wide analysis of the cyclin-dependent kinases (CDK) and cyclin family in molluscs[J]. Journal of Ocean University of China, 2021, 20(6): 1469-1482. doi: 10.1007/s11802-021-4758-4 [20] 翟欣影, 王丽华, 李艳华. PD-1、PD-L1在铂耐药卵巢上皮性癌组织中的表达及其临床意义[J]. 中华全科医学, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545ZHAI X Y, WANG L H, LI Y H. Expression of PD-1 and PD-L1 in platinum-resistant epithelial ovarian cancer tissues and their clinical significance[J]. Chinese Journal of General Practice, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545 -
点击查看大图
图(1) / 表(4)
计量
- 文章访问数: 7
- HTML全文浏览量: 3
- PDF下载量: 0
- 被引次数: 0
